$DARE
Dare Bioscience, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018029135 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q1 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $1.400M $1.050M
YoY Change 12.38% 600.0% 10400.0%
% of Gross Profit
Research & Development $1.447M $1.087M $280.8K
YoY Change 415.17% -76.64% -96.04%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $2.622M $7.677M $1.333M
YoY Change 96.61% 13.94% 22261.58%
Operating Profit -$2.622M -$7.677M -$1.333M
YoY Change 96.61% 22261.58%
Interest Expense -$300.0K
YoY Change -157.58%
% of Operating Profit
Other Income/Expense, Net $47.12K $11.74K
YoY Change -101.48%
Pretax Income -$2.570M -$7.670M -$1.630M
YoY Change 57.67% 3095.83% 8050.0%
Income Tax
% Of Pretax Income
Net Earnings -$2.574M -$7.666M -$1.630M
YoY Change 57.97% 20.93% -83.64%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$225.0K -$883.6K -$326.7K
COMMON SHARES
Basic Shares Outstanding 8.685M 4.986M
Diluted Shares Outstanding 5.638M

Balance Sheet

Concept 2018 Q3 2018 Q1 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.540M $15.63M $8.530M
YoY Change 11.84% 29.93% -77.59%
Cash & Equivalents $9.537M $15.63M $8.530M
Short-Term Investments
Other Short-Term Assets $550.0K $290.0K $1.140M
YoY Change -51.75% -88.16%
Inventory
Prepaid Expenses $549.9K $290.9K
Receivables
Other Receivables $80.28K $710.7K
Total Short-Term Assets $10.17M $15.94M $10.38M
YoY Change -2.02% 2.15% -73.52%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K
YoY Change
Goodwill $12.68M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $620.0K $690.0K $2.800K
YoY Change 22042.86% 200.0% -98.78%
Total Long-Term Assets $630.0K $685.2K $12.89M
YoY Change -95.11% 99.19% 1285.66%
TOTAL ASSETS
Total Short-Term Assets $10.17M $15.94M $10.38M
Total Long-Term Assets $630.0K $685.2K $12.89M
Total Assets $10.80M $16.63M $23.27M
YoY Change -53.58% 4.24% -42.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M $810.0K $840.0K
YoY Change 42.86% 25.78% -52.81%
Accrued Expenses $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.200M $807.6K $839.4K
YoY Change 42.96% -87.91% -94.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $10.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $10.00K $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.200M $807.6K $839.4K
Total Long-Term Liabilities $10.00K $0.00 $0.00
Total Liabilities $1.212M $810.5K $839.5K
YoY Change 44.39% -90.13% -96.43%
SHAREHOLDERS EQUITY
Retained Earnings -$19.90M -$3.100M
YoY Change -90.39%
Common Stock $35.75M $25.54M
YoY Change -83.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.584M $15.82M $22.43M
YoY Change
Total Liabilities & Shareholders Equity $10.80M $16.63M $23.27M
YoY Change -53.58% 4.25% -42.02%

Cashflow Statement

Concept 2018 Q3 2018 Q1 2017 Q3
OPERATING ACTIVITIES
Net Income -$2.574M -$7.666M -$1.630M
YoY Change 57.97% 20.93% -83.64%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.750M -$2.119M -$1.420M
YoY Change 93.66% 4137.77% -105.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$60.00K $9.920M
YoY Change -100.6%
Cash From Investing Activities -$60.00K $9.920M
YoY Change -100.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.10M
YoY Change 16190.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -90.00K $10.20M 0.000
YoY Change 10097.81% -100.0%
NET CHANGE
Cash From Operating Activities -2.750M -$2.119M -1.420M
Cash From Investing Activities -60.00K 9.920M
Cash From Financing Activities -90.00K $10.20M 0.000
Net Change In Cash -2.900M $8.065M 8.500M
YoY Change -134.12% 16030.36% -69.8%
FREE CASH FLOW
Cash From Operating Activities -$2.750M -$2.119M -$1.420M
Capital Expenditures $0.00
Free Cash Flow -$2.750M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
284206
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
549949
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9537463
CY2018Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
80278
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
311571
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
193495
CY2017Q4 us-gaap Assets Current
AssetsCurrent
8349118
CY2017Q4 us-gaap Goodwill
Goodwill
5187519
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
723191
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2621597
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1333421
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Assets
Assets
14259828
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1202912
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
966653
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
9292
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
392
CY2018Q3 us-gaap Liabilities
Liabilities
1212204
CY2017Q4 us-gaap Liabilities
Liabilities
967045
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-78032
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18080
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
25541210
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12230952
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
13292783
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14259828
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6047161
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6047161
dare License Fee
LicenseFee
350000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5187519
us-gaap Operating Income Loss
OperatingIncomeLoss
-13923755
us-gaap Operating Income Loss
OperatingIncomeLoss
-2041507
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
539896
us-gaap Net Income Loss
NetIncomeLoss
-13822263
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1629683
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18721
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9774
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-59952
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9774
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2593196
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1639457
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13882215
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2381514
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
us-gaap Profit Loss
ProfitLoss
-13822263
us-gaap Profit Loss
ProfitLoss
-2371740
us-gaap Depreciation
Depreciation
1263
us-gaap Share Based Compensation
ShareBasedCompensation
58538
us-gaap Share Based Compensation
ShareBasedCompensation
6953
us-gaap Paid In Kind Interest
PaidInKindInterest
316804
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
507000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-203928
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
238378
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
224433
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-193495
dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-105692
dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
2800
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
236259
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
659223
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
36776
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
8900
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
157
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7558047
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1579060
dare Cash Acquired Through Reverse Merger
CashAcquiredThroughReverseMerger
9918440
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11836
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
507000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-518836
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9918440
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
10114452
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10114452
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-59952
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-9774
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</p></div>
dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P3Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1066050
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
535031
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
59.48
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.27
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.62
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0290
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0290
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.23
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7500000
CY2017Q3 us-gaap Goodwill
Goodwill
12700000
CY2018Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5200000
CY2018Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
1089491
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q3 dare Number Of Clinical Stage Assets Assembled As Portfolio
NumberOfClinicalStageAssetsAssembledAsPortfolio
2
CY2018Q1 dare Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
11300000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10100000
CY2018Q3 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
144000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
dare Stock Option Modification Approval Date
StockOptionModificationApprovalDate
2017-03-19
CY2018Q3 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.70
CY2018Q1 dare Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0
dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0
dare Class Of Warrantor Right Number Of Securities Expired
ClassOfWarrantorRightNumberOfSecuritiesExpired
170
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3750833
CY2018Q3 dare Operating Lease Rentable Area
OperatingLeaseRentableArea
3169
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P37M
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2018Q3 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
8873
CY2018Q3 dare Percentage Of Increase In Annual Base Rent
PercentageOfIncreaseInAnnualBaseRent
0.04
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
315727
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5356623
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
576142
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5356623
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
576142

Files In Submission

Name View Source Status
0001564590-18-029135-index-headers.html Edgar Link pending
0001564590-18-029135-index.html Edgar Link pending
0001564590-18-029135.txt Edgar Link pending
0001564590-18-029135-xbrl.zip Edgar Link pending
dare-10q_20180930.htm Edgar Link pending
dare-20180930.xml Edgar Link completed
dare-20180930.xsd Edgar Link pending
dare-20180930_cal.xml Edgar Link unprocessable
dare-20180930_def.xml Edgar Link unprocessable
dare-20180930_lab.xml Edgar Link unprocessable
dare-20180930_pre.xml Edgar Link unprocessable
dare-ex311_9.htm Edgar Link pending
dare-ex312_18.htm Edgar Link pending
dare-ex321_11.htm Edgar Link pending
dare-ex322_16.htm Edgar Link pending
dare-ex41_345.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gl4iqqm5fy0t000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending